| Members |
acceptabilityId |
| 4b |
Preferred (foundation metadata concept) |
| 4c |
Preferred (foundation metadata concept) |
| 4d |
Preferred (foundation metadata concept) |
| 4e |
Preferred (foundation metadata concept) |
| 4f |
Preferred (foundation metadata concept) |
| 4p minus syndrome |
Acceptable (foundation metadata concept) |
| 4p partial monosomy syndrome |
Preferred (foundation metadata concept) |
| 4p partial monosomy syndrome (disorder) |
Preferred (foundation metadata concept) |
| 4p partial trisomy syndrome |
Preferred (foundation metadata concept) |
| 4p partial trisomy syndrome (disorder) |
Preferred (foundation metadata concept) |
| 4p16.3 microduplication syndrome |
Preferred (foundation metadata concept) |
| 4p16.3 microduplication syndrome (disorder) |
Preferred (foundation metadata concept) |
| 4p16.3 microduplication syndrome is a rare genetic syndrome that results from the partial duplication of the short arm of chromosome 4. It has a highly variable phenotype, principally characterised by psychomotor and language delay, seizures and dysmorphic features such as high forehead with frontal bossing, hypertelorism, prominent glabella, long narrow palpebral fissures, low set ears and short neck. Eye abnormalities (glaucoma, irregular iris pigmentation, hyperopia) have also been reported. |
Preferred (foundation metadata concept) |
| 4q partial monosomy syndrome |
Preferred (foundation metadata concept) |
| 4q partial monosomy syndrome (disorder) |
Preferred (foundation metadata concept) |
| 4q partial trisomy syndrome |
Preferred (foundation metadata concept) |
| 4q partial trisomy syndrome (disorder) |
Preferred (foundation metadata concept) |
| 4q21 microdeletion syndrome |
Preferred (foundation metadata concept) |
| 4q21 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
| 4q25 proximal deletion syndrome |
Preferred (foundation metadata concept) |
| 4q25 proximal deletion syndrome (disorder) |
Preferred (foundation metadata concept) |
| 4th |
Acceptable (foundation metadata concept) |
| 4th floor |
Acceptable (foundation metadata concept) |
| 4th generation HIV ELISA |
Acceptable (foundation metadata concept) |
| 4th left lumbar vein |
Acceptable (foundation metadata concept) |
| 4th nerve palsy |
Acceptable (foundation metadata concept) |
| 4th right lumbar vein |
Acceptable (foundation metadata concept) |
| 4x/wk |
Acceptable (foundation metadata concept) |
| 5 |
Preferred (foundation metadata concept) |
| 5 |
Preferred (foundation metadata concept) |
| 5 (qualifier value) |
Preferred (foundation metadata concept) |
| 5 French gauge |
Preferred (foundation metadata concept) |
| 5 French gauge (qualifier value) |
Preferred (foundation metadata concept) |
| 5 IU/0.1mL |
Acceptable (foundation metadata concept) |
| 5 International Units in 0.1mL |
Preferred (foundation metadata concept) |
| 5 International Units in 0.1mL (qualifier value) |
Preferred (foundation metadata concept) |
| 5 alpha-cholest-8(9)-en-3 beta-ol |
Acceptable (foundation metadata concept) |
| 5 aza 2 desoxycytidine |
Acceptable (foundation metadata concept) |
| 5 azacytidine |
Acceptable (foundation metadata concept) |
| 5 azadeoxycytidine |
Acceptable (foundation metadata concept) |
| 5 hours |
Preferred (foundation metadata concept) |
| 5 hours (qualifier value) |
Preferred (foundation metadata concept) |
| 5 level of presenting part in relation to ischial spines |
Preferred (foundation metadata concept) |
| 5 level of presenting part in relation to ischial spines (finding) |
Preferred (foundation metadata concept) |
| 5 o'clock position |
Preferred (foundation metadata concept) |
| 5 o'clock position (qualifier value) |
Preferred (foundation metadata concept) |
| 5 o'clock position on mammogram |
Preferred (foundation metadata concept) |
| 5 o'clock position on mammogram (finding) |
Preferred (foundation metadata concept) |
| 5 times a week |
Acceptable (foundation metadata concept) |
| 5% Acetic acid |
Preferred (foundation metadata concept) |
| 5% Acetic acid (substance) |
Preferred (foundation metadata concept) |
| 5' Nucleotidase measurement |
Preferred (foundation metadata concept) |
| 5' Nucleotidase measurement (procedure) |
Preferred (foundation metadata concept) |
| 5' acylphosphoadenosine hydrolase |
Preferred (foundation metadata concept) |
| 5' acylphosphoadenosine hydrolase (substance) |
Preferred (foundation metadata concept) |
| 5'-exonuclease |
Acceptable (foundation metadata concept) |
| 5'-methylthioadenosine phosphorylase |
Preferred (foundation metadata concept) |
| 5'-methylthioadenosine phosphorylase (substance) |
Preferred (foundation metadata concept) |
| 5'-nucleotidase |
Preferred (foundation metadata concept) |
| 5'-nucleotidase (substance) |
Preferred (foundation metadata concept) |
| 5'-polynucleotidase |
Acceptable (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase (FADH>2<) measurement |
Preferred (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) measurement |
Acceptable (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) measurement (procedure) |
Preferred (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase deficiency |
Preferred (foundation metadata concept) |
| 5,10-Methylenetetrahydrofolate reductase deficiency (disorder) |
Preferred (foundation metadata concept) |
| 5,10-methenyltetrahydrofolate synthetase |
Acceptable (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase (FADH>2<) |
Preferred (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) |
Acceptable (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) (substance) |
Preferred (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase gene analysis |
Preferred (foundation metadata concept) |
| 5,10-methylenetetrahydrofolate reductase gene analysis (procedure) |
Preferred (foundation metadata concept) |
| 5,25-dihydroxy cholecalciferol |
Preferred (foundation metadata concept) |
| 5,25-dihydroxy cholecalciferol (substance) |
Preferred (foundation metadata concept) |
| 5,6-dihydrouracil |
Preferred (foundation metadata concept) |
| 5,6-dihydrouracil (substance) |
Preferred (foundation metadata concept) |
| 5,8,11,14-eicosatetraenoic acid |
Acceptable (foundation metadata concept) |
| 5,8,11-eicosatrienoic acid |
Preferred (foundation metadata concept) |
| 5,8,11-eicosatrienoic acid (substance) |
Preferred (foundation metadata concept) |
| 5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase |
Preferred (foundation metadata concept) |
| 5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase (substance) |
Preferred (foundation metadata concept) |
| 5-ASA |
Acceptable (foundation metadata concept) |
| 5-Aminolaevulinate synthase |
Preferred (foundation metadata concept) |
| 5-Aminolevulinate synthase (substance) |
Preferred (foundation metadata concept) |
| 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one Kathon (3:1 in water) |
Preferred (foundation metadata concept) |
| 5-Chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one Kathon (3:1 in water) (product) |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol (product) |
Preferred (foundation metadata concept) |
| 5-Chloro-7-iodo-quinolinol (substance) |
Preferred (foundation metadata concept) |
| 5-FC |
Acceptable (foundation metadata concept) |
| 5-Fluorocytosine measurement |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA - 5-Hydroxyindole acetic acid |
Acceptable (foundation metadata concept) |
| 5-HIAA quantitative, urine |
Acceptable (foundation metadata concept) |
| 5-HPETE |
Acceptable (foundation metadata concept) |
| 5-HT - 5-hydroxytryptamine |
Acceptable (foundation metadata concept) |
| 5-HT secreting neuroendocrine tumour |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist |
Preferred (foundation metadata concept) |
| 5-HT3 receptor antagonist |
Preferred (foundation metadata concept) |
FHIR